A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b

Inclusion Criteria:

1. Subjects must be ≤ 6 years;

2. History of diagnosis of GA-I, and confirmed by gene mutation analysis with biallelicGCDH mutation;

3. At the time of screening, there was one of the obvious neurological manifestationsassociated with the following diseases, including macrocephaly, dystonia, andmotor/intellectual development Poor fertility, epilepsy, abnormal EEG;

4. Those who are receiving standard treatment recommended by the guidelines and whosesymptoms remain poorly controlled by the investigator;

5. Plasma GA and 3-OHGA levels were higher than the normal range during screening;

Exclusion Criteria:

1. Participation in gene therapy or stem cell transduction therapy at any time prior toscreening for this trial or participation in any other clinical trial within 3months prior to screening;

2. Recurrent seizures that are not suitable for surgery, based on Investigatorjudgment;

3. Current severe liver or kidney or cardiovascular disease or coagulation dysfunction,autoimmune deficiency, or uncontrolled autoimmune disease or need immunosuppressivelong-term treatment, poorly controlled diabetes (HBA1C ≥7% at screening) or highblood pressure;

4. Active viral infection (includes HIV or serology positive for hepatitis B or C orsyphilis);

5. Presence or history of malignancy;

6. Received systemic immunosuppressive therapy within 3 months prior to screening;

7. Received vaccine within 4 weeks prior to administration or plan to receive vaccinewithin 1 year after administration;

8. Plan to receive surgery during the study;

9. Current using medications including, drugs, herbal or OTC medications that stronglyinhibit or induce CYP3A4 or P-glycoprotein (P-gp), e.g., metoclopramide, grapefruitjuice, ketoconazole, erythromycin;

10. Abnormal brain structure, not suitable for lateral ventricle administration;

11. Abnormal laboratory test results, which are judged by the investigator not suitablefor surgery;

12. History of systemic hypersensitivity reaction to investigational product, theexcipients contained in the formulation, or prophylactic immunosuppressant;

13. Contraindicated use of corticosteroids and sirolimus;

14. Contraindicated with general anesthesia or sedation;

15. As judged by the investigator, unable to perform lateral ventricle puncture orOmmaya capsule implantation or lumbar puncture;

16. Unable to perform CT or MRI;

17. Poor compliance;

18. Any other situation where, judged by the investigator, the subject is not suitablefor participating in this study.